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Epidemiological studies indicate that overweight
and obesity are associated with increased cancer
risk. To study how obesity augments cancer risk
and development, we focused on hepatocellular
carcinoma (HCC), the common form of liver cancer
whose occurrence and progression are the most
strongly affected by obesity among all cancers. We
now demonstrate that either dietary or genetic
obesity is a potent bona fide liver tumor promoter
in mice. Obesity-promoted HCC development was
dependent on enhanced production of the tumor-
promoting cytokines IL-6 and TNF, which cause
hepatic inflammation and activation of the oncogenic
transcription factor STAT3. The chronic inflammatory
response caused by obesity and enhanced produc-
tion of IL-6 and TNF may also increase the risk of
other cancers.INTRODUCTION
Cancer development and progression are influenced by genetic,
epigenetic, and environmental factors. Epidemiological studies
are particularly effective for identification of cancer risk factors
but rarely elucidate the underlying mechanisms. For instance,
a link between inflammation and cancer was first suggested by
epidemiological studies, but the underlying mechanisms were
revealed through genetic and biochemical studies in appropriate
mouse models (Johansson et al., 2008; Karin, 2006; Mantovani
et al., 2008). Recently, a number of large-scale epidemiological
studies have pointed out that overweight and obesity, defined
by body mass index (BMI) higher than 25, result in a substantial
increase in cancer risk (Bianchini et al., 2002; Calle and Kaaks,
2004; Calle et al., 2003). It was pointed out that in men and
women, respectively, excess body weight results in up to 1.52-
or 1.62-fold increases in the relative risk of cancer-related death
(Calle et al., 2003). The actual increase in risk is very much
dependent on the type of cancer, and the largest increase incancer risk in individuals with high BMI was seen for hepatocel-
lular carcinoma (HCC), the most common form of liver cancer.
Men with BMI of 35–40 exhibited a staggering 4.52-fold increase
in relative HCC risk (Calle et al., 2003). Even amodest elevation in
BMI to the 25–30 range (grade 1 overweight) resulted in a signif-
icant increase in risk of death due to HCC, pancreatic cancer,
cancers of the gastrointestinal (GI) tract, and kidney cancer.
Given the prevalence of overweight and obesity in the Western
world (approximately two-thirds of US adults are overweight or
obese; Calle et al., 2003) and their rapid increase in developing
countries (there are about 300 million obese individuals world-
wide), even a modest 1.5- to 1.6-fold increase in relative cancer
risk represents amajor public health problem. Indeed, more than
90,000 cancer-related deaths per year in the US alone are linked
to excessive body weight (Calle et al., 2003).
Several mechanisms were proposed to explain how obesity
increases cancer risk, including the prevalence of type II dia-
betes and insulin resistance among obese individuals, which
result in elevated circulating concentrations of insulin and
insulin-like growth factor 1 (IGF-1), as well as increased produc-
tion of sex steroids and cytokines by adipose tissue (Calle and
Kaaks, 2004). However, these proposed mechanisms are based
on correlative studies and have not been critically evaluated.
Given the large impact of high BMI on HCC risk, we decided to
investigate the mechanisms by which obesity promotes HCC
development. Furthermore, an association between liver fat
accumulation or hepatosteatosis and HCC development has
been long known (Caldwell et al., 2004; El-Serag and Rudolph,
2007). Obesity-induced hepatosteatosis, together with its more
severe complication nonalcoholic steatohepatitis (NASH), clas-
sified as nonalcoholic fatty liver disease (NAFLD), which affects
up to 24% of the US population (Parekh and Anania, 2007),
may match in their etiologic impact hepatitis C virus (HCV) infec-
tion, the major HCC risk factor in the US and Japan (Caldwell
et al., 2004; El-Serag and Rudolph, 2007).
HCV infection and NAFLD, which can synergize to cause an
even greater increase in HCC risk, can both lead to endoplasmic
reticulum (ER) stress and accumulation of reactive oxygen
species (ROS) within liver parenchymal cells resulting in chronic
liver damage (Li et al., 2009; Parekh and Anania, 2007). It is
thought that chronic liver injury that results in compensatoryCell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc. 197
proliferation of differentiated hepatocytes, which are otherwise
quiescent, is one of the major pathogenic mechanisms under-
lying HCC development (Bisgaard and Thorgeirsson, 1996;
Fausto, 1999; Sakurai et al., 2006). The relevance of compensa-
tory proliferation as a tumorigenic mechanism is supported by
mouse genetic studies, using either the hepatic procarcinogen
diethylnitrosamine (DEN) as an inducer of HCC (Hui et al.,
2007; Maeda et al., 2005; Sakurai et al., 2006, 2008) or the condi-
tional and complete inactivation of NF-kB signaling needed for
maintenance of hepatocyte survival (Luedde et al., 2007).
We have used the DENmodel to investigate whether dietary or
genetic obesity is a direct promoter of HCC development and if
so dissect its mechanism of action. We now show that obesity is
a bona fide liver tumor promoter under conditions where DEN
administration to lean mice does not result in HCC induction.
We also demonstrate that one of the mechanisms that accounts
for the tumor-promoting effect of obesity is the low-grade inflam-
matory response it induces (Hotamisligil, 2006; Shoelson et al.,
2007), which results in elevated production of cytokines, such
as TNF and IL-6, which was found to positively correlate with
progression of chronic viral hepatitis to HCC in humans (Naka-
gawa et al., 2009; Wong et al., 2009). These cytokines are also
required for propagation of steatohepatitis.
RESULTS
Genetic and Dietary Obesity Strongly Promote
DEN-Induced Hepatocarcinogenesis
Although obesity is a well-established major HCC risk factor
(El-Serag and Rudolph, 2007), critical mechanistic insights to
its tumor-promoting activity are currently lacking. To be able to
employ genetic tools in our mechanistic analysis, we decided
to conduct our work with mice rather than other rodents.
Previous studies had revealed that hepatocyte-specific deletion
of the IKK regulatory subunit NEMO/IKKg results in spontaneous
liver damage, hepatosteatosis, liver fibrosis, and HCC develop-
ment (Luedde et al., 2007). When placed on high-fat diet
(HFD), Nemo/IkkgDhep mice exhibit the same protection from
obesity-induced insulin resistance previously found in liver-
specific IKKb knockout (IkkbDhep) mice (Arkan et al., 2005)
but display enhanced hepatosteatosis and elevated liver
damage and eventually develop four times more HCCs than
Nemo/IkkgDhep mice kept on normal chow (Wunderlich et al.,
2008). However, due to spontaneous liver damage and hepatos-
teatosis in Nemo/IkkgDhep mice, it is difficult to determine
whether obesity alone is a tumor promoter in this case. To
address this issue more definitively, we decided to use wild-
type (WT) C57/BL6mice which do not develop spontaneous liver
disease or cancer but are susceptible to the hepatic procarcino-
gen DEN, which effectively induces HCC formation when given
to 14-day-old mice (Vesselinovitch and Mihailovich, 1983).
We administered DEN (25mg/kg) to eithermale or femalemice
on postnatal day 14 and 4 weeks later placed the mice on either
normal chow (LFD) or high-fat diet (HFD), in which 60% of calo-
ries are fat derived (protocol #1, Figure S1A). As expected, male
mice maintained on HFD gained more weight than mice on LFD
(Figure S1C) and their relative liver weight was increased
(Figure S1D), as were liver triglycerides (TG) (Figure S1E). This198 Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc.was accompanied by increased serum TG (Figure S1F) and hep-
atosteatosis (Figure S1G). As expected, mice on HFD became
glucose intolerant (Figure S1H). Importantly, when analyzed at
9 months of age, mice kept on HFD exhibited many more
HCCs per liver than LFD-maintained mice (Figures 1A and 1B).
Dietary obesity also increased tumor size and incidence. A
similar effect was seen in female mice that were subjected to
the same HCC induction protocol (Figure 1C). Due to their lower
susceptibility to DEN-induced carcinogenesis (Naugler et al.,
2007), female mice exhibited a greater enhancement of HCC
incidence than male mice, although tumor multiplicity and its
enhancement by obesity were lower in females. HFD increased
body and liver weight as well as serum and liver TG also in female
mice (Figures S1I–S1K), but the effects on liver weight and TG
content were smaller than those seen in males.
To rule out the contribution of any potential carcinogens or
tumor promoters that could be present in HFD but not in normal
chow, we examined whether genetic obesity also enhances
HCC induction and development. As leptin-deficient mice
(LepOb) spontaneously develop obesity even when kept on
normal chow (Friedman et al., 1991; Pelleymounter et al.,
1995), we used them as a model for genetic obesity. We admin-
istrated 25 mg/kg DEN to 2-week-old LepOb male mice and
found that they exhibited greatly enhanced HCC development
relative to WT mice kept on LFD (Figures 1A and 1B). These
results strongly suggest that it is either obesity per se or hepatos-
teatosis that enhances HCC induction and development rather
than presence of unknown carcinogens or tumor promoters in
the particular HFD that we used.
Next, using conditions under which lean WT mice do not
develop any liver tumors when given DEN, we examined whether
dietary obesity functions as a tumor promoter. We took advan-
tage of the earlier observation that when DEN administration is
delayed until 4–6 weeks of age, it fails to induce HCC, even in
males, unless combined with a tumor promoter, such as pheno-
barbital (PB) (Ward et al., 1986). We kept WTmale mice on either
LFD or HFD for 10weeks prior to DEN administration at 16weeks
of age (protocol #2, Figure S1B). As expected, HFD consumption
initially resulted in weight gain and led to elevated serum TG
(Figures S2A and S2B). However, immediately after DEN admin-
istration, HFD-kept mice lost weight but regained it a few weeks
later. This sudden weight loss is likely to be due to enhanced
DEN-induced liver toxicity in obese mice, first noted when
HFD-kept mice were given the standard carcinogenic dose of
100 mg/kg DEN, which is not toxic in lean mice. Under these
conditions, all of the obese mice died within 13 days after DEN
administration (Figure S2C). Death was likely to have been
caused by liver failure as indicated by histological analysis
(Figure S2D), TUNEL staining (Figure S2E) and massive release
of the liver enzyme alanine aminotransferase (ALT) into the
circulation (Figure S2F). Obese mice also exhibited enhanced
DEN-induced ROS accumulation (Figure S2G). We therefore
reduced the dose of DEN used in this protocol (protocol #2,
Figure S1B) to 80 mg/kg. At this dose, despite initial weight
loss (Figure S2A), no lethality was observed in the HFD group.
Remarkably, close to 90% of mice kept on HFD developed
HCCwithout PB administration (Figures 1D and 1E). By contrast,
and as expected, mice kept on LFD did not develop any HCC
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Figure 1. Genetic and Dietary Obesity
Promote DEN-Induced Hepatocarcinogen-
esis
(A) Livers of male WT and LepOb mice kept on
normal chow (LFD) or high-fat diet (HFD) from
week 6 to week 36 after the administration of
DEN (25 mg/kg) at 2 weeks of age (protocol #1;
Figure S1A).
(B) Tumor multiplicity, size, and incidence in livers
of DEN-injected WT and LepOb male mice kept on
LFD (,) or HFD (-) as above. Results are aver-
ages ± standard deviation (SD) (n = 10–12).
(C) Tumor multiplicity, size, and incidence in livers
of WT females that were given DEN at 2 weeks of
age and fed as above. Results are averages ± SD
(n = 10–12).
(D) Livers of WT male mice given DEN (80 mg/kg)
at 16 weeks of age and kept on LFD or HFD from
week 6 to week 50 (protocol #2; Figure S1B).
When indicated, phenobarbital (PB) was given as
a tumor promoter in drinking water (0.05%) from
4 weeks after DEN administration until sacrifice.
Arrows indicate HCCs.
(E) HCC multiplicity, size, and incidence in WT
male mice treated as in (D).
Results are means ± SD (n = 10–13). *p < 0.05,
**p < 0.01, ***p < 0.001 denote significant differ-
ences between the groups. See also Figure S1
and S2.unless treated with PB after DEN administration. Furthermore,
the tumor-promoting effect of dietary obesity was at least as
strong as that of PB, a bona fide liver tumor promoter (Ward
et al., 1986).
Obesity Is Associated with Increased Cancer Cell
Proliferation
Enhanced DEN-induced hepatocyte death, as observed in IKKb
and p38a liver-specific knockout mice (IkkbDhep, p38aDhep), or
spontaneous liver damage inNemo/IkkgDhepmice are associated
with enhanced compensatory proliferation and augmented HCC
development (Hui et al., 2007; Luedde et al., 2007; Maeda et al.,
2005; Sakurai et al., 2008). Asmentioned above,DENadministra-
tion to obese mice induced more liver damage than in lean mice.
Nonetheless, HCCs in obese mice exhibited reduced apoptotic
cell death relative to HCCs in lean mice (Figures 2A and 2B).
Concurrently, HCCs in obese mice exhibited more proliferating
cells than HCCs in lean mice (Figures 2C and 2D), as well as
elevated cyclin D1 mRNA expression (Figure 2E). Thus, despite
the early increase in both DEN-induced apoptosis and compen-
satory proliferation in obese mice given DEN at 16 weeks of age
(Figure 2F), the long-term effect of obesity on HCC cell kinetics isCell 140, 197–208to decrease cell death and enhance cell
proliferation. These findings suggest that
alterations in signal transduction path-
ways that modulate hepatoma cell prolif-
eration independently of liver damage
and compensatory proliferation may
underlie the tumor-promoting effect of
obesity especially at later time points.To further examine this notion and separate effects of obesity
on tumor growth and progression from effects on tumor initia-
tion, we transplanted established hepatoma cells (derived
from a DEN-induced HCC) into 2-month-old lean mice that
were kept after tumor cell inoculation on either LFD or HFD for
4 weeks.We also inoculated the same number of hepatoma cells
into 8-month-old mice that were kept on HFD for the preceding
6 months or were genetically obese (LepOb). In all cases, tumor
growth was monitored over the course of 4 weeks after inocula-
tion. The greater the degree of host obesity, the faster the tumors
grew, reaching the largest size in LepOb mice (Figure 3). We
also treated some of the mice with the JAK inhibitor AG490
(Eriksen et al., 2001) to inhibit STAT3 activation (see below).
AG490 exerted a stronger inhibitory effect on tumor growth in
2-month-oldmice kept on HFD than inmice kept on LFD (Figures
3B and 3C) and as expected inhibited STAT3 phosphorylation
(Figure 3D).
Obese HCC-Bearing Mice Exhibit Elevated STAT3
and ERK Activation and Liver Inflammation
To identify signaling pathways responsible for enhanced hepa-
toma cell survival and proliferation, we first examined the effect, January 22, 2010 ª2010 Elsevier Inc. 199
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Figure 2. Obesity in HCC-Bearing Mice Is Associated with Increased Cancer Cell Proliferation and Reduced Apoptosis
HCC-bearing (protocol #1) male mice were subjected to histological and biochemical analyses at 9 months of age.
(A) Obesity reduces cell death in HCCs. Paraffin-embedded liver sections were TUNEL labeled (left panels) and counterstained with DAPI (right panels). Note the
presence of apoptotic cells in the tumor (T) area in lean mice. Magnification: 203.
(B) Numbers of apoptotic cells per field in (A) was determined by Image Tool software (n = 5).
(C) Obesity-enhanced cell proliferation in HCCs. Mice were BrdU pulsed 2 hr prior to sacrifice. Paraffin-embedded liver sections were stained with anti-BrdU
antibody.
(D) Numbers of BrdU-positive proliferating cells in (C) was determined with Image Tool software (n = 5).
(E) Expression of cyclin D1 mRNA in nontumor liver (NT) and tumors (T) was determined by qRT-PCR (n = 5–6). Values were normalized to cyclophilin mRNA.
(F) Mice kept on LFD or HFD for 10 weeks were injected with DEN (100 mg/kg) and their livers were isolated 48 hr after DEN administration and 2 hr after a BrdU
pulse. Paraffin-embedded liver sections were subjected to TUNEL and BrdU staining and positive cells were counted as above (n = 5).
All values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 denote significant differences between the groups.of obesity on several protein kinases known to be affected by
metabolic state. As expected (Tremblay et al., 2007; Um et al.,
2004), obesity was associated with decreased AKT phosphory-
lation and increased phosphorylation of the mTOR target S6
kinase and its substrate ribosomal protein S6 (Figure 4A). This
was observed in both normal livers and HCCs, strongly suggest-
ing that counter to a previous hypothesis (Calle and Kaaks,
2004), AKT activation, driven by insulin or IGF-1, is unlikely to
be responsible for enhanced cell survival and proliferation in
HCCs of obese individuals.
We next examined the effect of obesity on several signaling
molecules affected by inflammation and known to modulate
HCC development (Hui et al., 2007; Maeda et al., 2005; Sakurai
et al., 2006, 2008). Consistent with previous findings (Hirosumi
et al., 2002; Solinas et al., 2007), obese mice exhibited elevated
JNK activity in liver and even a larger increase in JNK phosphor-
ylation in HCCs (Figures 4B and 4C). HCCs in obese mice also
exhibited greatly elevated ERK phosphorylation relative to
HCCs of lean mice, but p38 phosphorylation was not altered in
obese liver and was even reduced in HCCs of obese mice
(Figures 4B and 4C). Remarkably, both nontumor liver tissue
and HCCs from obese mice displayed a substantial increase in
STAT3 phosphorylation, indicative of activation of this onco-
genic transcription factor (Figures 4B and 4C).200 Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc.Consistent with the increase in STAT3 activation, we found
that obese mice exhibited elevated circulating IL-6 (Figure 4D),
a potent STAT3-activating cytokine (Kamimura et al., 2003).
Elevated IL-6 mRNA was observed in both nontumor liver and
HCCs of obese mice (Figure 4E). Obesity also enhanced expres-
sion of TNF and IL-1b mRNAs (Figures 4F and 4G). The amount
of TNF protein was also greatly elevated in normal liver and HCC
from obese mice (Figure 4H). Elevated IL-6, TNF, and IL-1b
expression was also observed in obese female tumor-bearing
mice (Figures S3A–S3D). Consistent with elevated inflammatory
cytokines, livers from obese mice contained higher amounts of
macrophages and other leukocytes (Figures S3E–S3I).
Enhanced IL-6 Production Is Required
for Obesity-Induced Tumor Promotion
Given the marked increase in STAT3 phosphorylation and circu-
lating IL-6 in obese mice and their tumors, and knowing that IL-6
functions as a downstream mediator for both IL-1 and TNF (Ka-
mimura et al., 2003), we examined whether IL-6 is an important
component of the tumor-promoting mechanism activated by
obesity. To this end, we subjected WT and IL6/ mice to
protocol #1 (Figure S1A), in which DEN is given to 2-week-old
mice followed by either LFD or HFD. Remarkably, IL6/ male
mice, which developed much fewer HCCs than WT mice when
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Figure 3. Obesity Promotes Tumorigenic
Growth of Hepatoma Cells
(A) Two-month-old lean mice (2 M) were subcuta-
neously injected with established hepatoma cells
(2.5 3 106 cells/mouse) and kept on LFD or HFD
for 4 weeks after inoculation with (AG+) or without
(AG) AG490 (0.5 mg/mouse/day), a JAK inhibitor
that blocks STAT3 activation. The same number
of hepatoma cells was also transplanted into
8-month-old mice that were kept on HFD for the
preceding 6 months or were genetically obese
(LepOb). Tumor growth was monitored by
measurement with a caliper once a week, from
week 2 toweek 4. The images show representative
solid tumors dissected at week 4.
(B) Tumor growth measured over the course of a
2 week period in mice described in (A). The results
are means for 3–6 mice per group.
(C) Tumor sizes at week 4 post-inoculation are
shown as a histogram. Results are means ± SD
(n = 3–6).
(D) Tumors grown in mice given HFD without
(AG) or with (AG+) AG490, administered as
above, were collected at week 4 post-inoculation
and homogenized, and STAT3 phosphorylation
and expression were analyzed by immunoblotting.
All values represent means ± SD. *p < 0.05,
**p < 0.01 denote significant differences between
the groups.kept on LFD, an observation consistent with previous findings
(Naugler et al., 2007), hardly exhibited any augmentation of
tumor multiplicity, size, and incidence when placed on HFD
(Figures 5A and 5B). Importantly, the HCC load in IL6/ male
mice is identical to that of WT females (Naugler et al., 2007),
but unlike WT females, which produce more IL-6 when rendered
obese (Figures S3A and S3B) and develop more HCC, no signif-
icant increase in tumor load was seen in obese IL6/ males
(Figure 5C). Although IL6/males did not gain weight as rapidly
as WT males, they reached almost the same weight as WT mice
after 8 months on HFD (Figure 5D) and exhibited elevated serum
TG (Figure 5E). IL6/ males also showed increased liver TG
content after placement on HFD, although the extent of liver
TG accumulation was lower than in WT males. IL6/ male
mice also presented with elevated serum insulin after placement
on HFD, but the increase was not as robust as in obese WT
males (Figure 5E).
These data suggest that obesity-associated chronic elevation
in IL-6, a tumor-promoting cytokine whose expression can be
induced by both TNF and IL-1, is an important contributing factor
to liver tumorigenesis.
To better understand how the absence of IL-6 prevents
obesity-induced tumor promotion, we examined its effect on
stress/inflammation- and metabolism-responsive signaling
molecules. The absence of IL-6 prevented the obesity-induced
increase in JNK and ERK phosphorylation in nontumor liver
and HCCs and completely reversed the decrease in p38 phos-
phorylation previously seen in HCCs of obese mice (Figure 5F
and Figure S4A; compare to Figures 4B and 4C). As expected,
the absence of IL-6 prevented STAT3 phosphorylation in liver
and HCCs of obese mice (Figure 5F and Figure S4A). Interest-ingly, the IL-6 deficiency also prevented much of the obesity-
induced increase in S6 phosphorylation in both liver and HCCs
and partially attenuated the decrease in AKT phosphorylation
(Figure 5F and Figure S4A). These finding suggest that IL-6 is
not only required for STAT3, ERK, and JNK activation in the
obese liver, but it also contributes (indirectly, see below) to the
alterations in AKT and mTOR-S6K signaling.
TNF Receptor Signaling Is Required for Obesity-Induced
Tumor Promotion
In addition to IL-6, HFD increases expression of TNF, a proinflam-
matory cytokine that stimulates IL-6 production. We previously
found that TNF signaling via its type 1 receptor, TNFR1, is not
required for DEN-induced hepatocarcinogenesis in lean mice
(Naugler et al., 2007). Nonetheless, given the dramatic increase
in liver TNF production in obese mice (Figure 4H), we examined
whether TNFR1 signaling contributes to obesity-induced tumor
promotion. Remarkably, ablation of TNFR1 almost completely
abolished obesity-enhanced HCC development without
affecting HCC induction in lean mice (Figures 6A and 6B).
TNFR1/ mice, however, gained almost as much weight as
WTmice (Figure 6C). The rate of weight gain was also very similar
in the two strains.
Ablation of TNFR1 reduced JNK and p38 phosphorylation in
both lean and obese mouse livers and prevented the increase
in JNK activity associated with HCC development (Figure 6D
and Figure S4B). In addition, TNFR1/ mice did not show the
obesity-induced increase in STAT3 and ERK phosphorylation.
TNFR1 ablation also prevented the decrease in AKT phosphory-
lation seen in HFD-fed WT mice and attenuated the changes in
S6 phosphorylation (Figure 6D and Figure S4B).Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc. 201
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Figure 4. Obese HCC-Bearing Mice Exhibit Activated STAT3 and Elevated Expression of Inflammatory Cytokines
The HCC-bearing mice from Figure 2 were subjected to additional biochemical and gene expression analyses.
(A) Activation state ofmetabolically regulated protein kinases. Nontumor (NT) liver and HCC (T) were lysed and gel separated, and the activation (phosphorylation)
states of AKT and S6 kinase (S6K) were examined by immunoblotting.
(B) Nontumor (NT) liver and HCC (T) were analyzed for phosphorylation of JNK, ERK, p38, and STAT3 by immunoblotting as above. The bottom panel shows JNK
kinase assays in nontumor liver and HCCs of four different mice per dietary group.
(C) The results of several immunoblots similar to the one shown in (B), each representing a different mouse, were quantitated using Image J software and mean
values were determined (n = 3–4).
(D) Serum IL-6 in HCC-bearing mice was determined by ELISA (n = 10–12).
(E–G) Relative amounts of IL-6 (E), TNF (F), and IL-1b (G) mRNAs in nontumor (NT) liver and HCC (T) were determined by qRT-PCR and normalized to cyclophilin
mRNA (n = 6–8).
(H) TNF amounts in nontumor liver (NT) and HCC (T) were examined by immunoblotting of tissue lysates.
All values represent means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 denote significant differences between the groups. See also Figure S3.TNFR1 Signaling and IL-6 Promote Steatohepatitis
We further examined IL6/ and TNFR1/ tumor-bearing mice
to identify a common mechanism that could explain their resis-
tance to obesity-induced tumor promotion. As expected, the
absence of TNFR1 reduced the obesity-induced increase in
IL-6 production, resulting in lower-circulating IL-6 and less IL-6
mRNA in liver and in HCCs of obese mice (Figures 7A and 7B).
Conversely, the absence of IL-6 reduced the obesity-induced
increase in TNF production in tumor-bearing mice (Figure 7C).
The absence of either IL-6 or TNFR1 in tumor-bearing mice
reduced HFD-induced liver lipid accumulation (Figures 7D and
7E). The absence of either IL-6 or TNFR1 also reduced macro-
phage and neutrophil accumulation in livers of HFD-fed mice
(Figures 7F and 7G). We therefore conclude that both IL-6
and TNF signaling via TNFR1 are important for liver lipid202 Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc.accumulation (hepatosteatosis) and fat-induced liver inflamma-
tion (steatohepatitis), which together define NAFLD, a condition
that greatly increases the risk of HCC development (El-Serag
and Rudolph, 2007; Parekh and Anania, 2007).
DISCUSSION
Overweight and obesity greatly increase HCC risk, especially in
men (Calle and Kaaks, 2004; Calle et al., 2003). Despite the
magnitude of the effect and the very large number (900,000) of
individuals on which the epidemiological study that provided
this insight was based, the mechanisms by which obesity
increases risk of death from HCC and other cancers remained
unknown. We now describe that genetic or dietary obesity
greatly enhances the development of chemically induced HCC
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Figure 5. Enhanced IL-6 Production Is Required for Obesity-Induced Tumor Promotion
(A) Livers of WT and IL-6-deficient (IL6/) male mice that were kept on LFD or HFD after the administration of DEN (25 mg/kg) at 14 days of age.
(B) HCC multiplicity, size, and incidence (n = 10–12) in DEN-administered male mice of the indicated genotype kept on either LFD (,) or HFD (-).
(C) HCC multiplicity, size, and incidence (n = 10–12) in DEN-administered WT females or IL-6/ males of the indicated genotype kept on either LFD (,)
or HFD (-).
(D) Body weight gain during tumor development in WT and IL-6/ male mice kept on LFD or HFD after DEN administration.
(E) Serum and liver triglycerides (TG) in mice from (D) were determined by a colorimetric assay at 9 months of age. Serum insulin was determined by ELISA at the
same age (serum, n = 8–12; liver, n = 5).
(F) HCCs (T) and nontumor (NT) liver tissue from IL6/ male mice kept on either LFD or HFD were isolated, homogenized, and subject to immunoblot analysis
to determine the phosphorylation state of the indicated proteins. Shown are the results from two separate tumors for each condition.
All values are means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 denote significant differences between the groups. yp < 0.05, zp < 0.01 presents significant
differences from WT mice. See also Figure S4.in laboratory mice. By administering a chemical carcinogen
(DEN) to adult mice in which it fails to induce HCC on its own,
we demonstrated that obesity is a bona fide tumor promoter
whose effect is at least as strong as that of the validated liver
tumor promoter phenobarbital. Furthermore, we found that the
tumor-promoting effect of obesity in HCC depends to a largeextent on the low-grade inflammatory response it induces, which
involves elevated production of TNF and IL-6, both of which are
tumor-promoting cytokines (Lin and Karin, 2007).
While our work was being completed, it was described
that consumption of HFD resulted in increased formation of
preneoplastic lesions in response to DEN administration in ratsCell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc. 203
WT TNFR1-/-
LFD
HFD
A
D
B
0
10
20
30
40
50
60
70
WT TNFR1-/-
Tu
m
or
 m
ul
tip
lic
ity **
*
0
4
8
12
16
M
ax
im
al
 s
iz
e 
(m
m
)
WT TNFR1-/-
P=0.06
*
0
10
20
30
40
50
60
B
od
y 
w
t (
g)
WT LFD
WT HFD
TNFR1
-/- LFD
TNFR1
-/- HFD
0 2 4 6 8 M
C
NT T NT T
LFD HFD
STAT3
P-JNK
ERK
JNK
p38
P-p38
P-STAT3
P-ERK
P-AKT
AKT
P-S6
Tubulin
Figure 6. TNFR1 Signaling Is Required for
Obesity-Induced Tumor Promotion
(A) Livers of WT or TNFR1-deficient male mice
kept on LFD or HFD after DEN administration
(25 mg/kg) at 14 days of age.
(B) Tumor multiplicity and maximal sizes in
DEN-administered male mice of the indicated
genotypes kept on either LFD (,) or HFD (-)
(n = 10–13).
(C) Body weight gain during tumor development in
WT or TNFR1/ male mice kept on LFD or HFD
after DEN administration.
(D) Nontumor (NT) liver and HCC (T) from the mice
described in (A) were isolated, lysed, and gel
separated, and the phosphorylation states of the
indicated proteins were examined by immunoblot-
ting. Shown are the results for two separate mice
per condition.(Wang et al., 2009). However, these rats were not evaluated for
HCC and the mechanism underlying increased formation of pre-
neoplastic lesions was not determined. Another recent study
using Nemo/IkkgDhep mice, which spontaneously develop liver
damage, hepatosteatosis, and HCC on a normal diet (Luedde
et al., 2007), found that consumption of HFD enhanced the
development of hepatosteatosis and ensuing liver damage and
accelerated the appearance of liver tumors (Wunderlich et al.,
2008). However, the pre-existing hepatosteatosis and sponta-
neous liver damage in Nemo/IkkgDhep mice that are kept on
LFD prevented the conclusive demonstration that obesity per
se rather than chronic liver damage caused by the absence of
NF-kB is responsible for tumor promotion. Furthermore, the
mechanism by which obesity accelerates HCC development in
these mice was not determined. Enhanced liver tumorigenesis
is not unique to Nemo/IkkgDhep mice and was also seen upon
DEN administration to IkkbDhep and p38aDhep mice, which do
not manifest spontaneous liver damage or hepatosteatosis (Hui
et al., 2007; Maeda et al., 2005; Sakurai et al., 2008). It was
proposed that enhanced liver damage driven by ROS accumula-
tion, which gives rise to compensatory proliferation of initiated
hepatocytes, may explain augmented HCC development in all
of these mouse strains, which are more susceptible to DEN-
induced hepatotoxicity (Sakurai et al., 2006, 2008). Enhanced
liver damage is also seen in mice that have been rendered obese204 Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc.by consumption of HFD for 10 weeks and
then challenged with DEN. This elevated
hepatotoxic response may contribute to
the tumor-promoting effect of obesity.
We also found that obese mice accumu-
late more ROS both in nontumor liver
tissue and in HCCs (Figure S2G). How-
ever, this persistent ROS accumulation,
which is also seen during chronic HCV
infection (Wang and Weinman, 2006),
does not lead to increased cell death in
HCCs of obese mice. By contrast,
HCCs in obese mice display substantially
lower apoptotic rates than HCCs in leanmice (Figure 2A). Despite the reduction in apoptosis, HCCs in
obese mice contain more proliferating cells (Figures 2C and
2D), suggesting that enhanced compensatory proliferation
driven by hepatocyte death does not account for mid to late
tumor promotion in obese mice. Instead, mid to late tumor
promotion in obese mice correlates with enhanced proliferation
and reduced death of malignant hepatoma cells. Indeed, fully
initiated hepatoma cells exhibit higher tumor growth rates
when transplanted into obese mice, and this accelerated tumor
growth is slowed down by administration of a JAK inhibitor
that prevents STAT3 activation. Notably, IL-6 signaling through
ERK and STAT3 can reduce epithelial cell apoptosis while stim-
ulating cell proliferation, as recently found in colitis-associated
cancer (Grivennikov et al., 2009).
A survey of different signaling molecules in human HCC re-
vealed frequent activation of ERK and STAT3, especially in
HCCs with poor prognosis, as well as reduced p38 activation,
relative to the surrounding liver tissue (Calvisi et al., 2006). Similar
changes were observed in HCCs of WT obese mice (Figures 4A–
4C).We have also confirmed frequent STAT3 activation in human
HCC and, using liver-specific STAT3 knockout mice (Stat3Dhep),
found that this major transcriptional target for IL-6 is required for
HCC development (He et al., 2010). Furthermore, expression of
IL-6, a major STAT3 activator in the liver, is elevated in cirrhosis
and HCC (Tilg et al., 1992; Trikha et al., 2003). Elevated serum
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Figure 7. TNFR1 Signaling and IL-6 Support
Steatohepatitis
(A and C) Serum IL-6 (A) and TNF (C) were
measured by ELISA in HCC-bearing WT, IL6/,
or TNFR1/ mice kept on LFD (,) or HFD (-).
The analyses were done at 9 months of age
(n = 8–10).
(B) IL-6 mRNA amounts in HCC-bearing livers and
HCCs from WT or TNFR1/ mice kept on HFD or
LFD were measured by qRT-PCR at 9 months of
age. The bars depict the relative increase in
normalized mRNA amount, with the amount in
nontumor (NT) livers of leanmice given an arbitrary
value of 1.0 (n = 5–6).
(D) Liver fat accumulation in HCC-bearing WT and
IL6/mice kept on LFD or HFD was examined by
oil red O (ORO) staining of liver sections collected
at 9 months of age (magnification: 403).
(E) Liver TG levels in HCC-bearing WT, IL6/, or
TNFR1/ mice were determined at 9 months
of age.
(F and G) Macrophage (F and G) and neutrophil (G)
infiltration in nontumor liver and HCCs of lean and
obese 9-month-old WT, IL6/, and TNFR1/
male mice. Paraffin-embedded sections were
stained with F4/80- and Gr-1-specific antibodies
to visualize macrophages and neutrophils, respec-
tively. Results from F4/80 staining are shown in (F).
Data from several experiments (n = 4–5) were
quantitated with Image J software and were aver-
aged (G).
All values represent means ± SD. *p < 0.05,
**p < 0.01, **p < 0.001 denote significant differ-
ences between the groups.IL-6 also correlates with a higher risk of progression from chronic
viral hepatitis to HCC (Nakagawa et al., 2009; Wong et al., 2009).
A role for IL-6 in HCC development was first suggested by our
findings that differential IL-6 production following DEN-induced
liver damage accounts for the gender bias in HCC induction;
female mice produce 2-fold less IL-6 after DEN challenge than
males and therefore develop less HCC (Naugler et al., 2007).
Here we show that IL6/ male mice no longer respond to the
tumor-promoting effect of obesity, but female mice that can
produce more IL-6 when placed on HFD are susceptible to
obesity-induced tumor promotion, even though their basal
HCC induction rate is very low and similar to that of IL-6-deficient
males. Furthermore, inactivation of TNFR1, a receptor whoseCell 140, 197–208engagement by TNF contributes to
obesity-induced IL-6 production (Figures
7A and 7B), prevents obesity-promoted
hepatocarcinogenesis without affecting
DEN-induced hepatocarcinogenesis in
lean mice.
Although TNF and IL-6 may not be the
only mediators responsible for obesity-
induced tumor promotion, it is well-
established that their production is
elevated in obese mice due to the low-
grade inflammatory response caused bylipid accumulation (Arkan et al., 2005; Hotamisligil, 2006; Shoe-
lson et al., 2007; Solinas et al., 2007). In humans, IL-6 is thought
to be produced by adipose tissue during noninflammatory
conditions and is therefore considered to be an adipokine (Fried
et al., 1998; Mohamed-Ali et al., 1997). Not surprisingly, IL-6 in
serum shows positive correlation with BMI (Bastard et al.,
2000). IL-6 is also produced by Kupffer cells where it is induced
in response to hepatocyte death, which results in IL-1 release
(Sakurai et al., 2008). Not only IL-1, but TNF, whose production
is elevated in the obese liver, also leads to IL-6 production,
and our results reveal a substantial reduction in obesity-induced
IL-6 in TNFR1/mice. Regardless of its source, it is established
that IL-6 can propagate inflammation (Kamimura et al., 2003) and, January 22, 2010 ª2010 Elsevier Inc. 205
stimulate triglyceride secretion (Nonogaki et al., 1995). However,
the complete absence of IL-6 in mice was reported to have
controversial effects on adiposity. Whereas one study found
that IL6/mice became spontaneously obese as they got older
(Wallenius et al., 2002), another study failed to find any basal
alteration in body weight and fat deposition in IL6/ mice kept
on LFD (Di Gregorio et al., 2004). When placed on HFD, IL6/
mice were found to gain weight slower than WT mice but even-
tually did become obese (Di Gregorio et al., 2004) as seen in
our study (Figure 5D). Thus the absence of obesity-induced
tumor promotion in IL6/ mice is not due to their failure to
gain weight. Importantly, however, although total body weight
and serum triglycerides were still elevated, liver lipid accumula-
tion was substantially reduced in both IL6/ and TNFR1/
mice (Figures 7D and 7E). Thus, both TNF and IL-6 contribute
to the maintenance of hepatosteatosis. Furthermore, the
absence of TNFR1 or IL-6 prevented steatohepatitis, resulting
in much lower amounts of HFD-induced macrophage and
neutrophil accumulation in the liver relative to WT mice (Figures
7F and 7G). In humans, steatohepatitis is the more severe mani-
festation of NAFLD and it, rather than insulin resistance, is likely
to be the major contributor to obesity-induced tumor promotion
in the liver.
In addition to propagation of steatohepatitis, IL-6 leads to
STAT3 activation in hepatocytes (Naugler et al., 2007), and
STAT3 can stimulate the proliferation and progression of initiated
hepatocytes (He et al., 2010) and thus could be a molecular
mediator of tumor promotion. Given the involvement of STAT3
in several other cancers (Bromberg and Wang, 2009) and the
elevation in circulating IL-6 in obese and overweight individuals
(Bastard et al., 2000), it is likely that IL-6 and STAT3 may
contribute to the general enhancement of cancer risk by high
BMI. However, obesity, elevated IL-6, and activated STAT3 are
unlikely to cause cancer on their own. Even genetic alterations
that result in constitutive STAT3 activation in hepatocytes only
cause benign hepatic adenomas, unless combined with onco-
genic mutations (Rebouissou et al., 2009). Most likely, chronic
activation of the IL-6-STAT3 axis increases the likelihood of
expansion and further progression of transformed hepatocytes
that have acquired oncogenic mutations upon exposure to envi-
ronmental and dietary carcinogens. Notably, most xenobiotics
are metabolized within the liver, but sometimes this metabolism
results in the activation, rather than elimination, of procarcino-
gens (Sheweita and Tilmisany, 2003).
IL-6-induced STAT3 activation, however, is unlikely to be the
only tumor-promoting mechanism stimulated by obesity. It was
suggested that another tumor-promoting mechanism triggered
by obesity is enhanced AKT activation caused by the high
concentrations of circulating insulin and IGF-1 in overweight
and obese individuals (Calle and Kaaks, 2004). However, obesity
results in insulin resistance and actually leads to inhibition of AKT
activation as shown above. Thus AKT activation is unlikely to
contribute to enhanced HCC development in obese mice. A
more relevant player whose contribution merits further and dedi-
cated studies is mTOR, whose activity is elevated in the obese
liver (Figure 4A) and which is known to be an important regulator
of cell and tumor growth (Guertin and Sabatini, 2007). Themouse
models described above should be suitable for such studies.206 Cell 140, 197–208, January 22, 2010 ª2010 Elsevier Inc.EXPERIMENTAL PROCEDURES
Mice, Diet, Tumor Induction, and Analysis
IL-6-deficient (IL6/), TNFR1-deficient (TNFR1/), and leptin-deficient
(LepOb) mice on a C57BL/6 background were used along with corresponding
age-matched WT mice. All mice were maintained in filter-topped cages on
autoclaved regular chow diet (low-fat diet; LFD, composed of 12% fat, 23%
protein, 65% carbohydrates based on caloric content) or high-fat diet (HFD,
composed of 59% fat, 15% protein, 26% carbohydrates based on caloric
content; BioServ) and water at UCSD according to NIH Guidelines.
In the first DEN-induced HCC model (Figure S1A, protocol #1), DEN
(25 mg/kg) was injected intraperitoneally (i.p.) into 14-day-old mice. After
4 weeks, mice were separated into two dietary groups and fed either LFD or
HFD until sacrificed. In the second HCC model (Figure S1B, protocol #2),
mice were fed either LFD or HFD for 10 weeks prior to DEN administration
(i.p., 80 mg/kg) at 16 weeks of age, until sacrificed. Four weeks after DEN
administration, mice received water with or without PB (0.05%, Sigma) until
sacrificed. Serum insulin, IL-6, and TNF were measured by ELISA (eBio-
science) and ALT was detected using Biotron kit. Tumors in each liver lobe
were counted and measured with a caliper. Tumor and nontumor tissue was
collected and rapidly frozen for biochemical, histological, and immunochem-
ical analysis. In the HCC induction studies, mice were not treated with any
hormone or drug except when indicated (PB administration). In the transplant
study (Figure 3), mice did not receive any drug or hormone other than AG490
(LC Labs) when indicated.
Histological, Immunohistochemical, and Immunofluorescent Assay
Liver tissue was fixed in 10% formalin or embedded in Tissue-Tek OCT
compound (Sakura Finetek) for paraffin and frozen block preparation, respec-
tively. Paraffin-embedded liver tissue was used for H&E, TUNEL (Roche), and
immunohistochemical staining as described (Sakurai et al., 2008). TUNEL- and
BrdU-positive cells were quantified using Image tool. Frozen tissue sections
were stained with oil-red O (ORO) for lipid detection and dihydroethidine
(DHE) to detect ROS accumulation (Maeda et al., 2005).
Triglyceride, Insulin, and Glucose Measurement
Mice were fasted for 6 hr, after which their blood was analyzed for insulin
(ELISA: Crystal Chem Inc) and TG content (calorimetric assay: Diagnostic
Chemicals Limited). Liver TG was extracted in chloroform/methanol (2:1, v/v)
(Folch et al., 1957) and measured as above. For glucose tolerance test, mice
were injected with glucose (2 g/kg, i.p.) after 6 hr of fasting. Blood glucose
was measured using glucose meter (LifeScan).
Real-Time Quantitative PCR, Immunoblotting, and Kinase Assays
Total liver and HCC RNA was extracted with RNase Plus kit (QIAGEN) and
cDNA was synthesized using SuperScript II kit (Invitrogen). Real-time PCR
was performed using SYBR green (Bio-Rad) on aBio-Rad iQ5machine. Values
were normalized to cyclophilin mRNA amount. Liver lysates prepared in
standard RIPA buffer were gel separated and proteins were transferred to
PVDF membranes (Whatman). Membranes were probed with primary anti-
bodies and secondary HRP-conjugated antibodies (GE Healthcare UK) and
developed using ECL detection reagent (Pierce). Protein band intensity was
quantified using Image J software. JNK immunocomplex kinase assay was
performed using GST-cJun(1-79) as a substrate and a JNK1/2 antibody (Phar-
mingen) as described (Solinas et al., 2007).
Statistical Analysis
Data are presented as means ± standard deviation. Statistical significance
was calculated with a Student’s t test. Significance was accepted at the level
of p < 0.05 (*), p < 0.01 (**), or p < 0.001 (***).SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.cell.2009.12.052.
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